Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 3/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.35 |
| ▸ | GRM5 | P41594 | 6/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.32 |
| ▸ | DYRK2 | Q92630 | 2/20 | 0.31 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.31 |
| ▸ | TDP2 | O95551 | 1/20 | 0.31 |
| ▸ | NSD2 | O96028 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10286589 | 0.79 | S100A4 (0.38) | MAOBMAOAMAP3K14GRM5DYRK1A | |
| SCHEMBL15469476 | 0.79 | MAOB (0.38) | MAOBMAOAMAP3K14GRM5DYRK1A | |
| SCHEMBL23376851 | 0.79 | MAOB (0.38) | MAOBMAOAMAP3K14GRM5DYRK1A | |
| SCHEMBL23376935 | 0.79 | MAOB (0.41) | MAOBMAOAMAP3K14GRM5DYRK1A | |
| SCHEMBL15469486 | 0.75 | MAPT (0.37) | MAOBMAOAMAP3K14GRM5DYRK1A | |
| SCHEMBL25522617 | 0.75 | MAOA (0.35) | MAOBMAOAMAP3K14GRM5 | |
| SCHEMBL21935993 | 0.73 | DYRK1A (0.35) | DYRK1ANPC1POLBMAPTRAB9A | |
| SCHEMBL1516800 | 0.72 | MAP3K14 (0.40) | MAP3K14DYRK1ADYRK1BMAPTRAB9A | |
| SCHEMBL25832196 | 0.72 | GRM5 (0.34) | GRM5TDP2NSD2MAPT | |
| SCHEMBL22439215 | 0.71 | GRM5 (0.52) | MAOBMAOAGRM5TDP2NSD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230002426-A1 | CHIRAL SYNTHESIS OF A TERTIARY ALCOHOL | RECURIUM IP HOLDINGS, LLC | 2023-01-05 | — | — | US | disclosed |
| WO-2021097139-A1 | CHIRAL SYNTHESIS OF A TERTIARY ALCOHOL | RECURIUM IP HOLDINGS, LLC (US) | 2021-05-20 | — | — | WO | disclosed |
| US-8952009-B2 | Chroman derivatives as TRPM8 inhibitors | AMGEN INC. (US) | 2015-02-10 | — | — | US | disclosed |
| US-8952009-B2 | Chroman derivatives as TRPM8 inhibitors | AMGEN INC. (US) | 2015-02-10 | — | — | US | disclosed |
| US-20140045855-A1 | CHROMAN DERIVATIVES AS TRPM8 INHIBITORS | AMGEN INC. (US) | 2014-02-13 | — | — | US | disclosed |
| US-20140045855-A1 | CHROMAN DERIVATIVES AS TRPM8 INHIBITORS | AMGEN INC. (US) | 2014-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140045855-A1 | CHROMAN DERIVATIVES AS TRPM8 INHIBITORS | TRPM8, TRPM5, TRPM7 | MAOB 1631/4885MAOA 601/4885MAP3K14 1097/4885 |
| US-20230002426-A1 | CHIRAL SYNTHESIS OF A TERTIARY ALCOHOL | ADH1A, ADH1C, ADH5 | MAOB 1691/4885MAOA 2803/4885MAP3K14 755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.